Detalhe da pesquisa
1.
Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models.
Haematologica
; 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38841802
2.
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate Coronary Artery Lesions.
Med Sci Monit
; 30: e943956, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38720443
3.
Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors.
Hemasphere
; 8(3): e56, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486859
4.
Platelet microRNAs as Potential Novel Biomarkers for Antiplatelet Therapy with P2Y12 Inhibitors and Their Association with Platelet Function.
J Clin Med
; 13(1)2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38202070
5.
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Front Mol Biosci
; 9: 1073797, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533080